Interferon-gamma for Ovarian Cancer Treatment
Author Information
Author(s): Windbichler G H, Hausmaninger H, Stummvoll W, Graf A H, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C
Primary Institution: Department of Obstetrics and Gynaecology, University Hospital, Innsbruck, Austria
Hypothesis
Does adding interferon-gamma to standard chemotherapy improve outcomes for ovarian cancer patients?
Conclusion
Adding interferon-gamma to chemotherapy for ovarian cancer improves progression-free survival without increasing toxicity.
Supporting Evidence
- Progression-free survival improved from 38% in controls to 51% in the treatment group.
- Median times to progression were 17 months for controls and 48 months for the treatment group.
- Three-year overall survival was 58% for controls and 74% for the treatment group.
- Complete clinical responses were observed in 68% of patients receiving interferon-gamma.
Takeaway
This study tested a new medicine called interferon-gamma to see if it helps women with ovarian cancer live longer without their cancer getting worse. It worked better than the usual treatment.
Methodology
A randomized controlled trial comparing standard chemotherapy with and without interferon-gamma in ovarian cancer patients.
Limitations
The study did not reach median overall survival, and some results were not statistically significant.
Participant Demographics
Patients with FIGO stage Ic–IIIc ovarian cancer who had undergone primary surgery.
Statistical Information
P-Value
0.031
Confidence Interval
0.28–0.82
Statistical Significance
p=0.031
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website